CLINICAL TRIALS PROFILE FOR GOSERELIN ACETATE
✉ Email this page to a colleague
505(b)(2) Clinical Trials for goserelin acetate
| Trial Type | Trial ID | Title | Status | Sponsor | Phase | Start Date | Summary |
|---|---|---|---|---|---|---|---|
| New Formulation | NCT04060043 ↗ | Pilot Study to Evaluate the Effects of a Generic Goserelin Acetate in Patients With Prostate Cancer | Completed | Peptigroupe Inc | Early Phase 1 | 2017-02-21 | This open-label study is designed to obtain preliminary data on the efficacy of a new depot formulation of goserelin, Pepti 10.8mg, in ambulatory patients with carcinoma of the prostate who, in the opinion of the Investigator, is a candidate for androgen deprivation therapy, after a single injection. Secondarily, it is designed to assess the pharmacokinetics, safety profile and PSA response of this new formulation. |
| New Formulation | NCT04060043 ↗ | Pilot Study to Evaluate the Effects of a Generic Goserelin Acetate in Patients With Prostate Cancer | Completed | Peptigroupe Inc. | Early Phase 1 | 2017-02-21 | This open-label study is designed to obtain preliminary data on the efficacy of a new depot formulation of goserelin, Pepti 10.8mg, in ambulatory patients with carcinoma of the prostate who, in the opinion of the Investigator, is a candidate for androgen deprivation therapy, after a single injection. Secondarily, it is designed to assess the pharmacokinetics, safety profile and PSA response of this new formulation. |
| New Formulation | NCT04060043 ↗ | Pilot Study to Evaluate the Effects of a Generic Goserelin Acetate in Patients With Prostate Cancer | Completed | CMX Research | Early Phase 1 | 2017-02-21 | This open-label study is designed to obtain preliminary data on the efficacy of a new depot formulation of goserelin, Pepti 10.8mg, in ambulatory patients with carcinoma of the prostate who, in the opinion of the Investigator, is a candidate for androgen deprivation therapy, after a single injection. Secondarily, it is designed to assess the pharmacokinetics, safety profile and PSA response of this new formulation. |
| >Trial Type | >Trial ID | >Title | >Status | >Sponsor | >Phase | >Start Date | >Summary |
All Clinical Trials for goserelin acetate
| Trial ID | Title | Status | Sponsor | Phase | Start Date | Summary |
|---|---|---|---|---|---|---|
| NCT00002460 ↗ | Adjuvant Hormone Therapy in Treating Women With Operable Breast Cancer | Unknown status | Cancer Research UK | Phase 3 | 1987-09-01 | RATIONALE: Estrogen can stimulate the growth of breast cancer cells. Hormone therapy using tamoxifen may fight breast cancer by blocking the uptake of estrogen. PURPOSE: Phase III trial to compare the effectiveness of adjuvant therapy using tamoxifen or ovarian ablation with goserelin or both in treating women with stage I or stage II breast cancer. |
| NCT00002580 ↗ | Tamoxifen, Ovarian Ablation, and/or Combination Chemotherapy in Treating Premenopausal Women With Stage I, Stage II, or Stage IIIA Invasive Breast Cancer | Completed | Scottish Cancer Therapy Network | Phase 3 | 1993-06-01 | RATIONALE: Estrogen can stimulate the growth of breast cancer cells. Hormone therapy using tamoxifen may fight breast cancer by blocking the uptake of estrogen. Chemotherapy uses different ways to stop tumor cells from dividing so they stop growing or die. Combining chemotherapy with hormone therapy may kill more tumor cells. It is not yet known which treatment regimen is most effective for breast cancer. PURPOSE: Randomized phase III trial to compare the effectiveness of tamoxifen with that of ovarian ablation, and/or combination chemotherapy in treating premenopausal women with stage I, stage II, or stage IIIA breast cancer. |
| NCT00002582 ↗ | Tamoxifen, Ovarian Ablation, and/or Chemotherapy in Treating Women With Stage I, Stage II, or Stage IIIA Breast Cancer | Completed | Cancer Research Campaign Clinical Trials Centre | Phase 3 | 1993-06-01 | RATIONALE: Estrogen can stimulate the growth of breast cancer cells. Hormone therapy using tamoxifen may fight breast cancer by blocking the uptake of estrogen. Combination chemotherapy uses different ways to stop tumor cells from dividing so they stop growing or die. Combining hormone therapy with chemotherapy may kill more tumor cells. PURPOSE: Randomized phase III trial to compare the effectiveness of tamoxifen with or without chemotherapy and/or ovarian ablation in treating women with stage I, stage II, or stage IIIA breast cancer. |
| >Trial ID | >Title | >Status | >Sponsor | >Phase | >Start Date | >Summary |
Clinical Trial Conditions for goserelin acetate
Condition Name
Clinical Trial Locations for goserelin acetate
Trials by Country
Clinical Trial Progress for goserelin acetate
Clinical Trial Phase
Clinical Trial Sponsors for goserelin acetate
Sponsor Name
